HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.

AbstractHyper-IgD and periodic fever syndrome (HIDS) is a hereditary autoinflammatory syndrome, characterized by recurrent inflammatory attacks. Treatment of HIDS is difficult. Recently, the IL-1ra analogue anakinra was reported to be successful in aborting the IgD inflammatory attacks in a vaccination model. We report a clinical case of spectacular reduction of febrile attacks in a severe HIDS patient.
AuthorsM Cailliez, F Garaix, C Rousset-Rouvière, D Bruno, I Kone-Paut, J Sarles, B Chabrol, M Tsimaratos (Affiliation: AP-HM Timone-Enfants, F-13385, Marseilles Cedex 05, France.)
JournalJournal of inherited metabolic disease (J Inherit Metab Dis) Vol. 29 Issue 6 Pg. 763 (Dec 2006) ISSN: 1573-2665 [Electronic] Netherlands
PMID17103011 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Immunoglobulin D
  • Interleukin 1 Receptor Antagonist Protein
Topics
  • Fever (etiology, therapy)
  • Humans
  • Hypergammaglobulinemia (complications, therapy)
  • Immunoglobulin D (chemistry)
  • Inflammation
  • Interleukin 1 Receptor Antagonist Protein (therapeutic use)
  • Syndrome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD